Immunotherapy after radiotherapy for older esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding an immunotherapy medicine after radiotherapy can help control esophageal squamous cell cancer in people age 75 and older. It may help the immune system fight the cancer and improve outcomes after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 75 or older.
- You have confirmed esophageal cancer (type matters), and it is not suitable for surgery.
- You completed or are receiving radiotherapy plus chemotherapy, but you cannot tolerate chemotherapy.
- Your cancer has at least one measurable tumor spot on scans and has not grown into nearby major organs (specific depth stage).
- Your overall health is good enough for treatment (typical scale ECOG 0–1, enough lung and heart function, and basic blood/liver/kidney tests are within limits).
- You have not had prior anti-cancer treatment for esophageal cancer (including radiation, chemotherapy, surgery, or similar treatments).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
This trial tests whether adding the immunotherapy drug toripalimab and the chemotherapy pill capecitabine after standard chemoradiotherapy can help prevent esophageal cancer from coming back. It's for people with squamous cell esophageal cancer that hasn't spread far and who have just finished chemoradiotherapy.
This trial tests if adding radiation therapy after surgery improves outcomes for people with esophageal squamous cell cancer who received immunotherapy and chemotherapy before surgery but did not achieve a complete response. It aims to see if this approach can lower the chance of the cancer coming back.
This study looks at how safe and effective a combination of immunotherapy (a treatment that helps your immune system fight cancer) and standard chemotherapy plus radiation is for older adults (70+) with a type of esophageal cancer called squamous cell carcinoma who cannot have surgery or choose not to.
This trial looks at how best to add an immunotherapy “extra” before, during, and after standard chemoradiation for stage II–III esophageal squamous cell cancer that can’t be operated on. It may help reduce cancer that remains after treatment by targeting immune cells.
This trial tests combining chemoradiation with the immunotherapy drug iparomlimab for adults aged 70 and older with advanced esophageal cancer. The goal is to see if adding immunotherapy after standard chemoradiation improves outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma by AJCC V8 Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.